Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Yea...( ARDEE Ireland Aug. ...),Health

ARDEE, Ireland, Aug. 7 /PRNewswire-Firstcall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter ended June 30, 2009. Revenue in the quarter ended June 30, 2009 increased 7.1% to $250.8 million over the prior year quarter. The primary drivers of the increase in revenue were the net sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream which were partially offset by net sales declines of other products, primarily ESTROSTEP FE, SARAFEM and FEMHRT.

The Company reported net income of $56.0 million ($0.22 per diluted share) in the quarter ended June 30, 2009, compared with net income of $33.6 million ($0.13 per diluted share) in the prior year quarter, an increase of 66.9%. Cash net income ("CNI") in the quarter ended June 30, 2009 rose to $109.2 million ($0.44 per diluted share), an increase of 29.6% over the prior year quarter.

References in this release to "cash net income" or "CNI" mean the Company's net income adjusted for the after-tax effects of two non-cash items: amortization (including impairments, if any) of intangible assets and amortization (including write-offs, if any) of deferred loan costs related to the Company's debt. Reconciliations from the Company's reported results in accordance with US GAAP to CNI and adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") for all periods are presented in the tables at the end of this press release.

Revenue

Revenue in the quarter ended June 30, 2009 was $250.8 million, an increase of $16.6 million, or 7.1%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of DORYX, LOESTRIN 24 FE and ESTRACE Cream, which together contributed $28.0 million of revenue growth for the quarter ended June 30, 2009. The growth d
'/>"/>